Literature DB >> 3879200

Determination of chloroquine and its metabolites in urine: a field method based on ion-pair extraction.

Y Bergqvist, C Hed, L Funding, A Suther.   

Abstract

A new straightforward photometric method for the assay of the antimalarial drug chloroquine and its metabolites in urine is described. The method involves an ion-pair extraction procedure with dichloromethane using the acid-base indicator bromthymol blue as counter-ion. The ion pair formed with chloroquine in the organic phase is yellow, and absorbance is measured at lambda = 410 nm using a filter photometer. The absorbance is a linear function of concentration up to 400 mumol/l (120 mg/l) chloroquine. The method is suitable for the determination of chloroquine and its metabolites in urine down to a limiting concentration of about 10 mumol/l (3 mg/l). Additionally, the method is suitable for semiquantitative visual estimation of the concentration of chloroquine in urine. A single dose of 5 mg/kg chloroquine base could be determined in urine from two volunteers for at least 8 days after administration of the drug. The results obtained for the analysis of chloroquine and its metabolites with the colorimetric method described here correlate well with those obtained using high performance liquid chromatography.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3879200      PMCID: PMC2536441     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  7 in total

1.  PHOTOMETRIC DETERMINATION OF AMINES AND QUATERNARY AMMONIUM COMPOUNDS WITH BROMOTHYMOL BLUE. 4. EXTRACTION CONSTANTS AND CALCULATION OF EXTRACTION CONDITIONS.

Authors:  G SCHILL
Journal:  Acta Pharm Suec       Date:  1965-02

2.  Studies on the chemotherapy of malaria. III. The treatment of acute malaria with chloroquine.

Authors:  T WILSON; J F EDESON
Journal:  Med J Malaya       Date:  1954-12

3.  The eosin colour test of Dill and Glazko: a simple field test to detect chloroquine in urine.

Authors:  J Lelijveld; H Kortmann
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

4.  In-vivo and in-vitro assessment of chloroquine-resistant Plasmodium falciparum malaria in Zanzibar.

Authors:  I K Schwartz; D Payne; C C Campbell; O J Khatib
Journal:  Lancet       Date:  1983-05-07       Impact factor: 79.321

5.  An improved gas chromatographic method for the simultaneous determination of chloroquine and two metabolites using capillary columns.

Authors:  Y Bergqvist; S Eckerbom
Journal:  J Chromatogr       Date:  1984-03-09

6.  Sensitive method for the determination of chloroquine and its metabolite desethyl-chloroquine in human plasma and urine by high-performance liquid chromatography.

Authors:  Y Bergqvist; M Frisk-Holmberg
Journal:  J Chromatogr       Date:  1980-11-14

7.  Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria.

Authors:  O Walker; A H Dawodu; A A Adeyokunnu; L A Salako; G Alvan
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

  7 in total
  11 in total

1.  Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated plasmodium falciparum malaria.

Authors:  E Pussard; J P Lepers; F Clavier; L Raharimalala; J Le Bras; M Frisk-Holmberg; Y Bergqvist; F Verdier
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Pharmacokinetics of intramuscular amopyroquin in healthy subjects and determination of a therapeutic regimen for Plasmodium falciparum malaria.

Authors:  F Verdier; E Pussard; F Clavier; J Le Bras; C Gaudebout
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

3.  Colorimetric and thin-layer chromatographic methods for field assay of chloroquine and its metabolites in urine.

Authors:  D L Mount; L C Patchen; S B Williams; F C Churchill
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

4.  Field application of a colorimetric method of assaying chloroquine and desethylchloroquine in urine.

Authors:  R W Steketee; D L Mount; L C Patchen; S B Williams; F C Churchill; J M Roberts; D C Kaseje; A D Brandling-Bennett
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

5.  Effect of phospholipidosis on the cellular pharmacokinetics of chloroquine.

Authors:  Nan Zheng; Xinyuan Zhang; Gus R Rosania
Journal:  J Pharmacol Exp Ther       Date:  2010-12-14       Impact factor: 4.030

6.  Prolonged malaria prophylaxis with chloroquine and proguanil (chloroguanide) in a nonimmune resident population of an endemic area with a high prevalence of chloroquine resistance.

Authors:  D Gozal; C Hengy; G Fadat
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

7.  Adaptations of the Saker-Solomons test: simple, reliable colorimetric field assays for chloroquine and its metabolites in urine.

Authors:  D L Mount; B L Nahlen; L C Patchen; F C Churchill
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

8.  Efficacy of intramuscular amopyroquin for treatment of Plasmodium falciparum malaria in the Gabon Republic.

Authors:  C Gaudebout; E Pussard; F Clavier; D Gueret; J Le Bras; O Brandicourt; F Verdier
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

9.  Can use of hydroxychloroquine and azithromycin as a treatment of COVID-19 affect aquatic wildlife? A study conducted with neotropical tadpole.

Authors:  Thiarlen Marinho da Luz; Amanda Pereira da Costa Araújo; Fernanda Neves Estrela; Helyson Lucas Bezerra Braz; Roberta Jeane Bezerra Jorge; Ives Charlie-Silva; Guilherme Malafaia
Journal:  Sci Total Environ       Date:  2021-03-18       Impact factor: 7.963

Review 10.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.